

Richard Girling

Partner, Centerview Partners

Mr. Girling established the European business of Centerview Partners in London in 2009 and co-founded the Life Sciences practice. The Centerview Partners Healthcare team has advised on a number of significant transactions including: AstraZeneca on the \$119bn defence from Pfizer, Walgreens Boots Alliance on the \$6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Teva on its TL1A partnership transaction with Sanofi, CSL on its acquisition of Aventis Behring and its acquisition of Novartis' influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim's Roxane Laboratories, Galenica on its \$2bn IPO of Galenica Santé and separation of Vifor Pharma, Sanofi on its \$1.9bn acquisition of Kadmon and up to \$1.1bn sale of Enjaymo to Recordati, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its \$960mm sale to Angelini Pharma. Recently Mr. Girling has advised Zealand Pharma on its up to \$5.3bn collaboration and licensing agreement with Roche, EsoBiotec on its up to \$1bn sale to AstraZeneca and WBA on its \$23.7bn sale to Sycamore Partners. Mr. Girling established Merrill Lynch's European healthcare practice in 1998, and was Global Co Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is an Honorary Fellow of St Anne's College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.